Acumen Phase 1 Updates Target Engagement, Dosing Regimen and Safety Findings in Early Alzheimer’s

 Acumen presented data exploring target engagement modeling of ACU193, the first clinical-stage amyloid beta oligomer (AβO)-targeting antibody, to inform dose selection, plus further analyses of dose-related amyloid plaque reduction and clinical characteristics of ARIA-E, confirming proof-of-mechanism for ACU193

- Announced dose selection of 50 mg/kg and 35 mg/kg every 4 weeks for ACU193 treatment arms in upcoming Phase 2/3 trial based on significant target engagement approaching maximal effect

- New data from additional exploratory analyses of ACU193 presented in four additional poster presentations discussing clinical trial recruitment and diversity, pharmacokinetics and target engagement assay characteristics

https://www.globenewswire.com/news-release/2023/10/27/2768456/0/en/Acumen-Pharmaceuticals-Presents-Late-Breaker-Phase-1-Updates-Exploring-Novel-Target-Engagement-Dosing-Regimen-and-Safety-Findings-for-ACU193-in-Early-Alzheimer-s-Disease-at-the-16t.html